Loading...
Market
Which condition will Eligo Bioscience's CRISPR-based gene-editing tool target in human trials by end of 2025?
2
Resolution / Starting Odds
Inflammatory Bowel Disease • 25%
Obesity • 25%
Diabetes • 25%
Other • 25%
Clinical trial registries and official announcements
Story
Scientists at Eligo Bioscience Achieve CRISPR Breakthrough in Gut Microbiome Gene Editing
Jul 10, 2024, 10:35 PM
Scientists have successfully developed a CRISPR-based gene-editing tool that can modify bacterial populations in the gut microbiome of living mice. This breakthrough, achieved by the team at Eligo Bioscience and published in Nature, demonstrates the ability to perform in vivo bacterial genome editing with nearly 100% efficiency. The technique involves engineering a phage-derived vector to deliver a base editor, specifically targeting Escherichia coli colonizing the mouse gut. This represents a significant advancement in microbiome therapeutics and synthetic biology, offering new possibilities for manipulating the gut microbiome. Previously, the ability to manipulate the gut microbiome was restricted to pre- and probiotics, as noted by researcher David Bikard.
View original story
Similar markets
NTLA-2002 • 25%
Editas Medicine Therapy • 25%
Beam Therapeutics Therapy • 25%
Other • 25%
Editas Medicine • 25%
Intellia Therapeutics • 25%
CRISPR Therapeutics • 25%
Other • 25%
Phase 2 Trial Completion • 25%
FDA Approval • 25%
Commercial Launch • 25%
None of the Above • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Cystic fibrosis • 25%
Sickle cell anemia • 25%
Hemophilia • 25%
Other • 25%
Proof-of-concept data achieved • 25%
Partnership announcement • 25%
Regulatory approval submission • 25%
No major milestone achieved • 25%
Successful reduction in serum TTR levels • 25%
High adverse events lead to study halt • 25%
Modifications required for safety • 25%
Study continuation without major issues • 25%
Diabetes • 25%
Obesity • 25%
Heart Disease • 25%
Chronic Pain • 25%
Cancer • 25%
Autoimmune disorders • 25%
Infectious diseases • 25%
Other • 25%
Cancer • 25%
Neurodegenerative Diseases • 25%
Cardiovascular Diseases • 25%
Other • 25%